The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5-androstane-3,5,6-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2 values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.

The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5-androstane-3,5,6-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2 values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.

The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5-androstane-3,5,6-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2 values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.

The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5-androstane-3,5,6-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2 values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.

The present invention relates to four crystalline forms (crystalline forms A, B, C and D) of 5-androstane-3,5,6-triol (YC-6) and preparation methods therefor. The four crystalline forms have significant difference in their lattice parameters, 2 values and intensity in X-ray power diffraction, and melting points, etc. The study on its polymorphism is very important for further studying its effect, bioavailability and stability.

The present invention relates to novel steroidal compounds of formula (I), process for preparation of the same and composition comprising these compounds.

##STR00001##

The present invention relates to SHIP inhibitor compounds and methods for using these compounds. In particular, the present invention discloses the following methods: (i) a method of treating graft versus host disease in a subject; (ii) a method of inhibiting a SHIP1 protein in a cell; (iii) a method of selectively inhibiting a SHIP1 protein in a cell; (iv) a method for treating or preventing graft-versus-host disease (GVHD) in a recipient of an organ or tissue transplant; (v) a method of modulating SHIP activity in a cell expressing SHIP1 or SHIP2; (vi) a method of ex vivo or in vitro treatment of transplants; (vii) a method of inhibiting tumor growth and metastasis in a subject; (viii) a method of treating a hematologic malignancy in a subject; (ix) a method of inducing apoptosis of multiple myeloma cells; (x) a method of treating multiple myeloma in a subject; (xi) a method of inhibiting the proliferation of a human breast cancer cell; and (xii) a method of treating breast cancer in a subject.